Recent performance snapshot

Moderna (MRNA) has seen mixed share performance recently, with the stock edging up about 0.5% in the latest session and gaining roughly 5% over the past week, while the past month and past 3 months are slightly negative.

That recent 5.2% 7 day share price return sits against a much stronger year to date share price return of 61.7%, while the 3 year total shareholder return is down 61.2%. This means near term momentum contrasts with a weaker longer term record.

If Moderna has your attention, it can be useful to widen the lens and see how other healthcare AI driven opportunities are trading using the 40 healthcare AI stocks

With the stock up strongly year to date but trading below the average analyst price target, the key question is whether Moderna is still mispriced or if the recent rebound already reflects its future growth potential.

Most Popular Narrative: 8.3% Overvalued

Moderna last closed at $49.91 against a narrative fair value of $46.10, so the current price sits modestly above that modeled estimate.

The dramatic expansion and advancement of Moderna's mRNA pipeline beyond COVID-19, including recent positive late-stage data and upcoming filings for flu, RSV, CMV, oncology, and rare diseases, are likely to diversify the revenue base, capitalize on the rising global burden of infectious and chronic diseases, and materially boost future top-line growth.

Read the complete narrative. Read the complete narrative.

Curious what kind of revenue ramp, margin shift, and future P/E multiple would support that fair value and price gap? The narrative leans on ambitious growth targets, a sizeable margin swing, and a premium earnings multiple that many investors might usually associate with faster growing sectors.

Result: Fair Value of $46.10 (OVERVALUED)

However, there are still clear pressure points, including the large litigation settlement obligations and uncertainty around how much the flu and broader vaccine portfolio will deliver.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Next Steps

With sentiment mixed between recent gains and longer term weakness, this is a moment to act quickly and test the story against the numbers yourself. To understand what is driving optimism, take a closer look at the company's 1 key reward.

Looking for more investment ideas?

If Moderna has sharpened your curiosity, do not stop here. Broaden your watchlist now so you are not late to the next opportunity.

• Target quality at a discount by scanning companies that appear mispriced on strong fundamentals using the 44 high quality undervalued stocks.
• Lock in potential income streams by reviewing stocks with hefty yields in the 8 dividend fortresses.
• Prioritize resilience by filtering for companies with robust finances and consistent metrics through the solid balance sheet and fundamentals stocks screener (48 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.